PureTech Health PLC - Asset Resilience Ratio
PureTech Health PLC (PRTC) has an Asset Resilience Ratio of 10.72% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PRTC liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how PureTech Health PLC's Asset Resilience Ratio has changed over time. See shareholders equity of PureTech Health PLC for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down PureTech Health PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRTC stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $59.30 Million | 10.72% |
| Total Liquid Assets | $59.30 Million | 10.72% |
Asset Resilience Insights
- Moderate Liquidity: PureTech Health PLC has 10.72% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
PureTech Health PLC Industry Peers by Asset Resilience Ratio
Compare PureTech Health PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for PureTech Health PLC (2012–2024)
The table below shows the annual Asset Resilience Ratio data for PureTech Health PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.38% | $86.67 Million | $602.63 Million | -5.23pp |
| 2023-12-31 | 19.61% | $136.06 Million | $693.97 Million | -8.89pp |
| 2022-12-31 | 28.50% | $200.23 Million | $702.65 Million | +28.63pp |
| 2021-12-31 | -0.14% | $-1.28 Million | $946.01 Million | +0.04pp |
| 2020-12-31 | -0.17% | $-1.70 Million | $989.99 Million | -3.37pp |
| 2019-12-31 | 3.20% | $30.09 Million | $941.18 Million | -27.10pp |
| 2018-12-31 | 30.29% | $133.83 Million | $441.76 Million | -4.14pp |
| 2017-12-31 | 34.43% | $117.03 Million | $339.85 Million | -39.01pp |
| 2016-12-31 | 73.44% | $219.41 Million | $298.75 Million | +18.42pp |
| 2015-12-31 | 55.02% | $179.78 Million | $326.75 Million | +54.51pp |
| 2014-12-31 | 0.51% | $1.17 Million | $228.03 Million | -10.41pp |
| 2013-12-31 | 10.92% | $1.83 Million | $16.77 Million | +4.79pp |
| 2012-12-31 | 6.13% | $1.18 Million | $19.18 Million | -- |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more